TG Therapeutics, Inc. (TGTX) News
Filter TGTX News Items
TGTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TGTX News Highlights
- For TGTX, its 30 day story count is now at 7.
- Over the past 19 days, the trend for TGTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- TG and AAN are the most mentioned tickers in articles about TGTX.
Latest TGTX News From Around the Web
Below are the latest news stories about TG THERAPEUTICS INC that investors may wish to consider to help them evaluate TGTX as an investment opportunity.
TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should KnowIn the latest trading session, TG Therapeutics (TGTX) closed at $14.79, marking a -0.6% move from the previous day. |
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Call TranscriptTG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It […] |
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual MeetingNEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeti |
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue EstimatesTG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsConference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ETNEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2022 was a pivotal year for TG with the approval of BRIUMVI for relapsing forms of Multiple Sclerosis, and 2023 is off to an exciting sta |
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business UpdateConference call to be held Tuesday, February 28, 2023 at 8:30 AM ETNEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, February 28, 2023 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2022 and provide a business outlook for 2023. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U. |
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each of the presentations are included below. Michael S. Weiss, Chairman and Chief Executive Officer |
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should KnowTG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day. |
Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis TreatmentGrowth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment. |
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and |